Notable Calls
RSS feedNotablecalls@gmail.com
Wednesday, September 26, 2007
Baird on Genzyme (Nasdaq:GENZ) - Actionable
- Baird is out with an interesting call on Genzyme (NASDAQ:GENZ) saying they recently learned that AMGN plans to conduct an additional Phase II study on its polymer-based phosphate binder AMG 223 (f/k/a ILY-101). Firm recalls AMGN acquired AMG 223 through its June acquisition of Ilypsa; they think this agent is widely viewed as Renagel's chief threat.
Firm thinks this could be a significant development for two reasons:
* First, they (and they believe most observers) had anticipated this agent would enter Phase III straight away, based on Ilypsa's Phase II dose-ranging study.
* Second, while they do not know whether this drug's original dose-escalation Phase II study will be at ASN (Oct 31-Nov 5), they speculate that if it is detailed, it may not be as impressive as some had feared, given that AMGN has embarked on this additional Phase II study.
Maintains Outperform and $75 tgt on GENZ. Notes they are incremental buyers on this news.
Notablecalls: Expect to see some buy intrest in GENZ following these comments.
posted by notablecalls # 8:13 AM 
Archives
June 2006 July 2006 August 2006 September 2006 October 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 July 2007 August 2007 September 2007 October 2007 November 2007 December 2007 January 2008 February 2008 March 2008 April 2008 May 2008 June 2008 July 2008 August 2008 September 2008 October 2008
